Clinical trials: Streptococcal Infections, open to volunteers
Rheumatic Heart Disease, Rheumatic Heart Disease in Children
Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor
This is a Phase I/IIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor.
- Conditions
- Rheumatic Heart Disease, Rheumatic Heart Disease in Children, Vaccine Adverse Reaction, Rheumatic Diseases
- Trial name
- StreptInCorVac (NCT07078357)
- Testing
- StrepIncor
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Ankylosing Spondylitis, Rheumatic Arthritis
Biomarkers in Inflammatory Rheumatic Diseases Diagnosis
Ankylosing spondylitis (AS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are three diseases where early diagnosis remains a major challenge.
- Conditions
- Ankylosing Spondylitis, Rheumatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- BIRDD (NCT06778343)
- Where
- Portugal
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Universidade Nova de Lisboa
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Rheumatic Heart Disease in Children
School-based Program for the Prevention of Rheumatic Heart Disease in Endemic Regions
The overall objective of the PREVENT trial is to evaluate the effectiveness of an integrated, school-based program for the prevention of rheumatic heart disease (RHD) in regions with an endemic pattern of RHD.
- Trial name
- PREVENT (NCT06720272)
- Testing
- School nurse program
- Where
- 2 sites in Nepal, Zambia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Thomas Pilgrim
Pneumococcal Disease
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07573462
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 78 sites in United States, Argentina and 8 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants Aged 2-23 Months
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
- Trial name
- NCT06800261
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Infections, Immunization Programs
Randomized Controlled Trial Of Text Messages To Increase Pneumococcal Vaccination In Adults In Chile.
The goal of this randomized controlled trial is to learn if text message reminders sent through WhatsApp increase pneumococcal vaccination coverage in adults turning 65 years old in Chile.
- Conditions
- Pneumococcal Infections, Immunization Programs, Vaccination Coverage, Text Messaging (Intervention)
- Trial name
- PNEUMO-SMS (NCT07659470)
- Testing
- WhatsApp text message reminder for pneumococcal vaccination
- Where
- Chile
- Volunteers
- 40,753 people, healthy volunteers welcome
- Sponsor
- Pablo Tomás Valenzuela García
Cystitis, Erysipelas
Hospital at Home for Elderly Acute Ill Patients
Many elderly patients with uncomplicated treatment courses are admitted unnecessarily, which is a burden for the patient and society. Studies show that Hospital at Home (HaH) treatment is an alternative to hospitalization.
- Conditions
- Cystitis, Erysipelas, Pneumonia
- Trial name
- NCT05360914
- Testing
- Hospital at Home (HaH) treatment, Standard hospital admission
- Where
- 3 sites in Denmark
- Volunteers
- 849 people
- Sponsor
- Defactum, Central Denmark Region
Osteoporosis, Inflammatory Rheumatism
Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases.
- Trial name
- Rh-GIOP (NCT02719314)
- Testing
- Glucocorticoid treatment
- Where
- Germany
- Volunteers
- 10,000 people
- Sponsor
- Prof Dr Frank Buttgereit
Group A Streptococcal (GAS) Pharyngitis
Short Versus Standard Amoxicillin for Pediatric Strep Throat
The purpose of this study is to compare 5-day vs 10-day amoxicillin for strep throat in children.
- Trial name
- NCT07845812
- Testing
- 5 day short course antibiotic treatment, 10 day standard of care antibiotic treatment
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- The University of Texas Health Science Center, Houston
Streptococcal Pharyngitis
Stopping Strep Throat With Antibodies in Healthy Adults.
This research group has previously established a safe and reliable model of experimental human streptococcal pharyngitis (a 'strep throat' human challenge model).
- Trial name
- CHIVAS-IgG (NCT07864350)
- Testing
- Streptococcus pyogenes M1 challenge strain, Intravenous immunoglobulin (IVIG)
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Neurodevelopmental Disorders, Autism Spectrum Disorder
Patterns of Neurodevelopmental Disorders
The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
- Conditions
- Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome
- Trial name
- NCT06213090
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Richard Frye
Pneumococcal Pneumonia, Rotavirus Enteritis With Hypovolemic Shock
Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial
Background: China's healthcare system for children faces significant challenges, particularly due to the limited pediatric service capacity of primary healthcare institutions.
- Conditions
- Pneumococcal Pneumonia, Rotavirus Enteritis With Hypovolemic Shock, Hand-foot-and-mouth Disease, Acute Appendicitis
- Trial name
- NCT06699433
- Testing
- Virtual standardized patients (VSPs), Case teaching manuals, Case teaching videos
- Where
- 3 sites in China
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- Southern Medical University, China
Rheumatic Fever, Valvular Heart Diseases
Improving Management and Secondary Prevention Through Azithromycin Comparative Trial in Rheumatic Heart Disease in Nigeria)- IMPACT-RHD Nigeria
Background: Nigeria, among other Low and Middle-income countries, bears one of the highest burdens of RHD in Africa, affecting young to middle-aged adults within their productive years.
- Conditions
- Rheumatic Fever, Valvular Heart Diseases, Valvular Cardiomyopathy
- Trial name
- IMPACT-RHD (NCT07625228)
- Testing
- Benzathine Penicillin, Azithromycin (Azithro)
- Volunteers
- 474 people
- Sponsor
- Ladoke Akintola University of Technology, Ogbomoso, Nigeria
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.
- Trial name
- NCT07300644
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 3 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Rheumatic Fever, Rheumatic Heart Disease in Children
ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
The ACT4RHD trial is a multicentre, pragmatic, multi-arm, open-label adaptive platform trial addressing multiple therapeutic questions in patients with ARF and carditis.
- Conditions
- Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart Disease
- Trial name
- ACT4RHD (NCT07830108)
- Testing
- Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 600 people
- Sponsor
- Starship Child Health, Te Toka Tumai Auckland
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Rheumatic Heart Disease
Testing a Registry-Based Strategy (ACT+) to Reduce Loss to Follow-Up in Rheumatic Heart Disease Screening in Uganda
This study aims to improve follow-up care after positive rheumatic heart disease (RHD) screening in Northern Uganda. It will identify barriers and co-develop an enhanced ACT+ strategy, then evaluate its effectiveness in…
- Trial name
- SHIELD 2 (NCT07606131)
- Testing
- The ACT+ Strategy
- Where
- Uganda
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hiv, Meningococcal Infections
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
MENPI is an investigator-initiated single-centre randomized controlled trial which aims to assess the efficacy and safety of meningococcal and pneumococcal vaccination in adults living with HIV receiving antiretroviral treatment.
- Conditions
- Hiv, Meningococcal Infections, Pneumococcal Infections
- Trial name
- MENPI (NCT04875819)
- Testing
- Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Thomas Benfield
Streptococcal Infections
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant.
- Trial name
- NCT07085702
- Testing
- Low dose Strep A Alum, Medium dose Strep A Alum, High dose Strep A Alum
- Where
- 2 sites in Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline